## ABVX: ABIVAX Société Anonyme - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 14.6% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. MRS_5 (16.2%) even more extended - blow-off risk elevated.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($121.58)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Abivax Stock Surges with Acquisition Buzz**
- Source: StocksToTrade | 20251222T153959 | Bullish | Relevance: 100%
- Abivax SA stock has surged by 16.64% due to promising trial results, FDA designations, and significant acquisition buzz, particularly involving Eli Lilly. The company's upcoming inclusion in the Nasdaq Biotechnology Index and positive analyst price target revisions also contribute to heightened investor enthusiasm. Despite strong operational figures and cash reserves, a widened quarterly loss presents some financial complexity.

**2. ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)**
- Source: ts2.tech | 20251222T120959 | Bullish | Relevance: 100%
- ABIVAX (ABVX) stock is surging due to renewed takeover speculation involving Eli Lilly and its addition to the Nasdaq Biotechnology Index. While the Eli Lilly rumors are unconfirmed, the NBI inclusion is official and provides increased visibility and potential passive investment flows. The long-term outlook for ABIVAX hinges on its lead clinical program, obefazimod, in late-stage development for ulcerative colitis, with Phase 3 maintenance results and Phase 2b Crohn's disease results expected in 2026.

**3. Abivax jumps on media reports of Eli Lilly takeover bid**
- Source: TradingView — Track All Markets | 20251222T090959 | Bullish | Relevance: 100%
- Abivax shares (ABVX) surged 8% following unconfirmed media reports of a potential takeover bid by Eli Lilly (LLY). A French outlet suggested Eli Lilly met with France's Treasury to discuss regulatory approval for acquiring Abivax. While Abivax declined to comment on market rumors, speculation surrounding a deal has intensified, with one trader suggesting a meeting with the Treasury indicates an agreed-upon price in principle.

**4. 12 Health Care Stocks Moving In Monday's Pre-Market Session**
- Source: Benzinga | 20251222T120959 | Bullish | Relevance: 100%
- This article details the pre-market movements of 12 health care stocks on a Monday. It highlights both gainers and losers, providing their stock performance percentage, current stock price, and market capitalization. Abivax, Scinai Immunotherapeutics, and Edgewise Therapeutics were among the top gainers, while DBV Technologies, Impact BioMedical, and Intercure experienced declines.

**5. Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251220T070901 | Somewhat-Bullish | Relevance: 100%
- Abivax SA (NASDAQ:ABVX) has received a "Moderate Buy" consensus rating from thirteen analysts, with an average 12-month price target of $128.73. The biopharmaceutical company, focused on chronic inflammatory diseases, reported a quarterly loss and currently trades around $114.94. Several hedge funds and institutional investors have recently adjusted their stakes in Abivax, which has a market capitalization of $8.96 billion.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Citizens | $131 | $114 | +15% |
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Citizens | main | Market Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Momentum building: MRS_20 improving +21.9% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (7.9x), low leverage (D/E 0.28). Revenue growth strong at 605% YoY. Analyst sentiment positive (1 raises, avg +15%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.9B |
| Beta | -0.11 |
| 52W Range | $4.77 - $139.62 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -7.3% to 14.6% (+21.9% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (14.6% > 10.0%), caution on chasing. MRS_5 at 16.2% confirms short-term momentum alignment. AM_20 at 15.3% shows strong absolute momentum above own 20MA. Outperforming sector by 14.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 14.62% (CS: 98) | Strong |
| RSI_14 | 66.4 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.153x | Above |
| vs SMA50 | 1.273x | Above |
| vs SMA200 | 2.623x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $138.72
- **Stop Loss:** $121.58 (12.4% risk)
- **Target:** $155.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 70
- **Position Value:** $9,710.40
- **Portfolio %:** 9.71%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*